BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Satoi S, Yamamoto T, Yamaki S, Sakaguchi T, Sekimoto M. Surgical indication for and desirable outcomes of conversion surgery in patients with initially unresectable pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg. 2020;4:6-13. [PMID: 32021953 DOI: 10.1002/ags3.12295] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Ishido K, Hakamada K, Kimura N, Miura T, Wakiya T. Essential updates 2018/2019: Current topics in the surgical treatment of pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg 2021;5:7-23. [PMID: 33532676 DOI: 10.1002/ags3.12379] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Wei K, Hackert T. Surgical Treatment of Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2021;13:1971. [PMID: 33923884 DOI: 10.3390/cancers13081971] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Mita N, Iwashita T, Ichikawa H, Iwasa Y, Uemura S, Murase K, Shimizu M. Clinical Outcomes of Conversion Surgery after FOLFIRINOX in Patients with Unresectable Advanced Pancreatic Cancer: A Retrospective Cohort Study at a Single Center. J Clin Med 2021;10:2848. [PMID: 34199125 DOI: 10.3390/jcm10132848] [Reference Citation Analysis]
4 Gray S, de Liguori Carino N, Radhakrishna G, Lamarca A, Hubner RA, Valle JW, Mcnamara MG. Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma. European Journal of Surgical Oncology 2022. [DOI: 10.1016/j.ejso.2022.02.014] [Reference Citation Analysis]
5 Ushida Y, Inoue Y, Oba A, Mie T, Ito H, Ono Y, Sato T, Ozaka M, Sasaki T, Saiura A, Sasahira N, Takahashi Y. Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study. Ann Surg Oncol 2022. [PMID: 35294658 DOI: 10.1245/s10434-022-11503-6] [Reference Citation Analysis]
6 Yamada S, Fujii T, Yamamoto T, Takami H, Yoshioka I, Yamaki S, Sonohara F, Shibuya K, Motoi F, Hirano S, Murakami Y, Inoue H, Hayashi M, Hashimoto D, Murotani K, Kitayama J, Ishikawa H, Kodera Y, Sekimoto M, Satoi S. Conversion surgery in patients with pancreatic cancer and peritoneal metastasis. J Gastrointest Oncol 2021;12:S110-7. [PMID: 33968431 DOI: 10.21037/jgo-20-243] [Reference Citation Analysis]
7 Yamada S, Fujii T, Yamamoto T, Takami H, Yoshioka I, Yamaki S, Sonohara F, Shibuya K, Motoi F, Hirano S, Murakami Y, Inoue H, Hayashi M, Murotani K, Kitayama J, Ishikawa H, Kodera Y, Sekimoto M, Satoi S. Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis. Br J Surg 2020;107:1811-7. [PMID: 32638367 DOI: 10.1002/bjs.11792] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
8 Yanagimoto H, Satoi S, Yamamoto T, Yamaki S, Hirooka S, Kotsuka M, Ryota H, Ishida M, Matsui Y, Sekimoto M. Benefits of Conversion Surgery after Multimodal Treatment for Unresectable Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2020;12:E1428. [PMID: 32486418 DOI: 10.3390/cancers12061428] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
9 Kang MJ, Kim SW. Current status and perspectives of the future of pancreatic surgery: Establishment of evidence by integration of "art" and "science". Ann Gastroenterol Surg 2021;5:738-46. [PMID: 34755005 DOI: 10.1002/ags3.12494] [Reference Citation Analysis]
10 Schizas D, Koumpoura A, Galari M, Economopoulou P, Vailas M, Sotiropoulou M, Dimitroulis D, Maroulis I, Felekouras E. A personalized approach to pancreatic ductal adenocarcinoma and its application in surgical practice. Per Med 2021;18:613-27. [PMID: 34676789 DOI: 10.2217/pme-2021-0031] [Reference Citation Analysis]
11 Matsumoto R, Arigami T, Matsushita D, Okubo K, Tanaka T, Yanagita S, Sasaki K, Noda M, Kita Y, Mori S, Kurahara H, Ohtsuka T. Conversion surgery for stage IV gastric cancer with a complete pathological response to nivolumab: a case report. World J Surg Oncol 2020;18:179. [PMID: 32693806 DOI: 10.1186/s12957-020-01954-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
12 Li Y, Shen J, Cheng CS, Gao H, Zhao J, Chen L. Overexpression of pyruvate dehydrogenase phosphatase 1 promotes the progression of pancreatic adenocarcinoma by regulating energy-related AMPK/mTOR signaling. Cell Biosci 2020;10:95. [PMID: 32782783 DOI: 10.1186/s13578-020-00457-5] [Reference Citation Analysis]
13 Yang HK, Park MS, Choi M, Shin J, Lee SS, Jeong WK, Hwang SH, Choi SH. Systematic review and meta-analysis of diagnostic performance of CT imaging for assessing resectability of pancreatic ductal adenocarcinoma after neoadjuvant therapy: importance of CT criteria. Abdom Radiol (NY) 2021. [PMID: 34331549 DOI: 10.1007/s00261-021-03198-2] [Reference Citation Analysis]
14 Hashimoto D, Satoi S, Yamamoto T, Yamaki S, Ishida M, Sakaguchi T, Hirooka S, Ikeura T, Inoue K, Sekimoto M. Validation of the triple-checked criteria for drain management after pancreatectomy. J Hepatobiliary Pancreat Sci 2021. [PMID: 34330147 DOI: 10.1002/jhbp.1030] [Reference Citation Analysis]
15 Mataki Y, Kurahara H, Idichi T, Tanoue K, Hozaka Y, Kawasaki Y, Iino S, Maemura K, Shinchi H, Ohtsuka T. Clinical Benefits of Conversion Surgery for Unresectable Pancreatic Ductal Adenocarcinoma: A Single-Institution, Retrospective Analysis. Cancers (Basel) 2021;13:1057. [PMID: 33801465 DOI: 10.3390/cancers13051057] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 Gupta N, Yelamanchi R. Pancreatic adenocarcinoma: A review of recent paradigms and advances in epidemiology, clinical diagnosis and management. World J Gastroenterol 2021; 27(23): 3158-3181 [PMID: 34163104 DOI: 10.3748/wjg.v27.i23.3158] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Kato H, Horiguchi A, Ito M, Asano Y, Arakawa S. Essential updates 2019/2020: Multimodal treatment of localized pancreatic adenocarcinoma: Current topics and updates in survival outcomes and prognostic factors. Ann Gastroenterol Surg 2021;5:132-51. [PMID: 33860134 DOI: 10.1002/ags3.12427] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Timmer FEF, Geboers B, Nieuwenhuizen S, Schouten EAC, Dijkstra M, de Vries JJJ, van den Tol MP, Meijerink MR, Scheffer HJ. Locoregional Treatment of Metastatic Pancreatic Cancer Utilizing Resection, Ablation and Embolization: A Systematic Review. Cancers (Basel) 2021;13:1608. [PMID: 33807220 DOI: 10.3390/cancers13071608] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Ushida Y, Inoue Y, Oba A, Mie T, Ito H, Ono Y, Sato T, Ozaka M, Sasaki T, Saiura A, Sasahira N, Takahashi Y. ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel? Is Surgery Really Worthwhile after Sufficient Chemotherapy? Ann Surg Oncol. [DOI: 10.1245/s10434-022-11621-1] [Reference Citation Analysis]
20 Wei K, Hackert T. Surgical Treatment of Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2021;13:1971. [PMID: 33923884 DOI: 10.3390/cancers13081971] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Oba A, Ho F, Bao QR, Al-Musawi MH, Schulick RD, Del Chiaro M. Neoadjuvant Treatment in Pancreatic Cancer. Front Oncol. 2020;10:245. [PMID: 32185128 DOI: 10.3389/fonc.2020.00245] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 14.5] [Reference Citation Analysis]
22 Wu YHA, Oba A, Lin R, Watanabe S, Meguid C, Schulick RD, Del Chiaro M. Selecting surgical candidates with locally advanced pancreatic cancer: a review for modern pancreatology. J Gastrointest Oncol 2021;12:2475-83. [PMID: 34790408 DOI: 10.21037/jgo-21-119] [Reference Citation Analysis]
23 Oba A, Del Chiaro M, Satoi S, Kim SW, Takahashi H, Yu J, Hioki M, Tanaka M, Kato Y, Ariake K, Wu YHA, Inoue Y, Takahashi Y, Hackert T, Wolfgang CL, Besselink MG, Schulick RD, Nagakawa Y, Isaji S, Tsuchida A, Endo I. New criteria of resectability for pancreatic cancer: A position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS). J Hepatobiliary Pancreat Sci 2021. [PMID: 34581016 DOI: 10.1002/jhbp.1049] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]